BPC-157 peptide claims: what med spas aren't telling you

What did @opalmedspa actually say?

Dr. Ari, the platform's physician, made three specific claims about BPC-157: that it "helps to reduce inflammation," that it helps "with healing and recovery from injuries, especially sports injuries," and that it helps "with gut health." The video is short and promotional, but the claims are concrete enough to check.

Credit where it's due: the doctor didn't promise a cure, didn't name a specific condition BPC-157 treats definitively, and didn't throw out dosing numbers. For a 30-second med spa TikTok, that's a relatively restrained presentation. But three claims were still made, and they deserve scrutiny.

Does the science back this up?

Partially, but with a major caveat: almost all of the supporting research is in animals. Human clinical trials on BPC-157 are essentially nonexistent, which matters a lot when a clinic is actively enrolling patients.

On the anti-inflammatory and tissue repair side, rodent studies are genuinely interesting. Sikiric et al. (2018, Current Pharmaceutical Design) documented BPC-157's effects on tendon, muscle, and bone healing in rat models, showing accelerated repair via growth hormone receptor pathways. For gut health, the peptide was originally derived from human gastric juice, and animal studies show protection against NSAID-induced ulcers and inflammatory bowel-like conditions (Sikiric et al., 2012, Journal of Physiology-Paris). These are real findings. They are just not human findings yet.

The sports injury angle is the most loosely supported. "Sports injuries" is a broad category, and no randomized controlled trial in humans has confirmed BPC-157 accelerates recovery in athletes specifically.

What did they get wrong (or right)?

The claims themselves aren't fabricated, but presenting animal-derived data to a consumer audience without that qualifier is a meaningful omission. When a doctor says "this peptide helps with healing," most viewers hear clinical confirmation, not "this works in rats and we're extrapolating."

The gut health claim is actually the best-supported of the three, given that BPC-157's origin is gastric tissue and the gastric/intestinal protective effects in rodents are consistently replicated across multiple research groups. That's worth acknowledging.

The sports injury claim is the weakest. It's the most commercially appealing claim, and it has the least direct evidence. Saying it's good for athletes specifically implies outcome data that doesn't exist in controlled human trials.

BPC-157 is also not FDA-approved and remains a research compound. The FDA issued a guidance in 2023 removing BPC-157 from the list of bulk substances that can be compounded, citing a lack of clinical evidence. That regulatory context was absent from the video entirely.

What should you actually know?

BPC-157 is not approved by the FDA for any indication. In 2023, the FDA proposed removing it from permissible compounding substances, which has direct implications for clinics currently offering it. Anyone considering this peptide should know they are participating in something closer to experimental use than established treatment.

That doesn't mean the science is worthless. The mechanistic research is legitimately interesting, particularly around angiogenesis, nitric oxide modulation, and mucosal protection (Chang et al., 2011, Regulatory Peptides). But interesting preclinical data and proven clinical outcomes are not the same thing.

If you're exploring BPC-157, ask the prescribing physician directly: what human evidence are you drawing on? What is the regulatory status of this compound at your pharmacy? Are you tracking outcomes? A physician who can answer those questions clearly is one worth trusting. One who can't, isn't.